The global atopic dermatitis market is expanding as the increasing prevalence of atopic dermatitis across both pediatric and adult populations, rising disease awareness, improved diagnosis rates, and growing demand for advanced therapies such as biologics accelerate treatment adoption and market expansion.

The market was valued at approximately USD 6.09 billion in 2024, about USD 6.56 billion in 2025, and is projected to reach roughly USD 13.8 billion by 2035, growing at a CAGR of approximately 7.72%. Growth is supported by increasing prevalence of atopic dermatitis, rising disease awareness, improved diagnosis rates, and growing demand for advanced therapies such as biologics.marketresearchfuture

Chronic atopic dermatitis holds the largest market share at 61%, reflecting a significant demand due to the long-term nature of the condition. This segment is characterized by continuous management and treatment options that cater to patients needing ongoing care.

Pediatric atopic dermatitis is emerging as the fastest-growing segment, driven by increased awareness and diagnosis rates among younger populations, leading to a rise in effective therapeutic options tailored for children.

Topical corticosteroids currently dominate the atopic dermatitis market, accounting for the largest share of 54% among treatment types. These treatments are widely preferred due to their effectiveness in managing inflammation and are often first-line therapies recommended by healthcare providers.

Biologics have emerged as a potent alternative, gaining traction as more patients seek novel treatments that target specific pathways involved in the pathophysiology of atopic dermatitis. This shift is prompting healthcare professionals to adopt biologics more frequently, indicating a trend towards personalized medicine in dermatology.

North America led the market with over 45% share, generating around USD 2.74 billion in revenue. Key players include AbbVie, Sanofi, Eli Lilly, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Galderma, Amgen, and Pfizer.

Read more: Atopic Dermatitis Market Size, Share

People Also Ask

Q1. What is driving the atopic dermatitis market?
Increasing prevalence, rising disease awareness, improved diagnosis rates, and growing demand for advanced therapies such as biologics are major drivers.

Q2. Which treatment type leads the market?
Topical corticosteroids lead with 54% market share, while biologics are the fastest-growing treatment type.

Tags: atopic dermatitis, eczema, biologics, topical corticosteroids, dermatology